Long COVID plays role in severe and selective neuropsychological impairments

Article

Self-reported survey data “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

Image Credit: © Khunatorn - stock.adobe.com

Survey data that was self-reported by 54 individuals who responded to the survey “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported. (Image credit: Adobe Stock/Khunatorn)

Marie-LuiseKieseler and Brad Duchaine, PhD students from Dartmouth College, Hanover, NH, reported that COVID-19 can cause severe and selective neuropsychological impairments after long COVID.1 These impairments can be life-altering and persistent.

They described the case of a 28-year-old woman, Annie, who had normal face recognition, ie, prosopagnosia, before she developed COVID-19 in March 2020. Two months later, she noticed that she was having difficulties recognizing faces when her COVID-19 symptoms relapsed. The problems with face recognition have persisted.

Kieseler and Duchaine assessed Annie’s abilities to recognize faces using 4 tests: a famous faces test and a Doppelganger test to assess her long-term face identity recognition abilities, and 2 tests of unfamiliar face identity recognition; her navigational skills were also markedly impaired after she developed COVID-19. They reported that she performed poorly on all 4 tests. However, she performed normally on tests of face detection, face identity perception, object recognition, scene recognition, and non-visual memory.

Survey data that was self-reported by 54 individuals who responded to the survey “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

In Annie’s case, she resumed working from home in April 2020. However, she could not recognize her father when she saw him again after she recovered from her illness and she could not differentiate him from her uncle.

“My dad’s voice came out of a stranger’s face,” she said.

She also reported that she experienced problems getting around a grocery store and identifying her car in the lot.

The researchers summarized, “Annie's results indicate that COVID-19 can produce severe and selective neuropsychological impairment similar to deficits seen following brain damage, and it appears that high-level visual impairments are not uncommon in people with long COVID."

Reference
1. Kieseler M-L, Duchaine B. Persistent prosopagnosia following COVID-19. Cortex. 2023; Published online March 9, 2023; https://doi.org/10.1016/j.cortex.2023.01.012Get rights and content
Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.